tag novo-nordisk 
XTalks
APRIL 29, 2022
The promising trial results could pose a threat to Danish drugmaker Novo Nordisk’s GLP-1 agonist drug Wegovy (semaglutide), which has dominated the obesity drug market since its launch in 2021. Lilly’s Tirzepatide Takes on Novo Nordisk’s Semaglutide. Wegovy had a price tag of $1,297 a month when it was first launched.
Pharmaceutical Technology
MAY 15, 2023
Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 13, 2023
PLM and generative modelling for de novo degisn This session will begin with chairperson’s remarks from Victor Greiff, PhD, Associate Professor, Immunology, University of Oslo. Jendrik Schöppe, PhD, Senior Scientist, Novo Nordisk, on: ‘Stablised GPCRs for antibody discovery’.
Pharmaceutical Technology
NOVEMBER 30, 2022
Several other treatments, like Novo Nordisk’s CagriSema (semaglutide + cagrilintide), are expected to follow after showing encouraging Phase II data. Novo Nordisk is another company leading the charge in this field. However, Novo Nordisk’s anti-obesity therapeutics have had rough rollouts following their approvals.
Pharmaceutical Technology
NOVEMBER 30, 2022
Several other treatments, like Novo Nordisk’s CagriSema (semaglutide + cagrilintide), are expected to follow after showing encouraging Phase II data. Novo Nordisk is another company leading the charge in this field. However, Novo Nordisk’s anti-obesity therapeutics have had rough rollouts following their approvals.
Expert insights. Personalized for you.
98 
Let's personalize your content